75. Kramer, K.; Pandit-Taskar, N.; Humm, J.L.; Zanzonico, P.B.; Haque, S.; Dunkel, I.J.; Wolden, S.L.; Donzelli, M.; Goldman, D.A.; Lewis, J.S.; et al. A phase II study of radioimmunotherapy with intraventricular (131) I-3F8 for medulloblastoma. *Pediatr. Blood Cancer* **2018**, *65*. [CrossRef]

76. Herbertson, R.A.; Tebbutt, N.C.; Lee, F.T.; Gill, S.; Chappell, B.; Cavicchiolo, T.; Saunder, T.; O'Keefe, G.J.; Poon, A.; Lee, S.T.; et al. Targeted chemoradiation in metastatic colorectal cancer: A phase I trial of 131I-huA33 with concurrent capecitabine. *J. Nucl. Med.* **2014**, *55*, 534–539. [CrossRef]

77. Cahan, B.; Leong, L.; Wagman, L.; Yamauchi, D.; Shibata, S.; Wilczynski, S.; Williams, L.E.; Yazaki, P.; Colcher, D.; Frankel, P.; et al. Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma. *Cancer Biother. Radiopharm.* **2017**, *32*, 258–265. [CrossRef]

78. Sahlmann, C.O.; Homayounfar, K.; Niessner, M.; Dyczkowski, J.; Conradi, L.C.; Braulke, F.; Meller, B.; Beissbarth, T.; Ghadimi, B.M.; Meller, J.; et al. Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study. *Cancer* **2017**, *123*, 638–649. [CrossRef] [PubMed]

79. Allen, B.J.; Singla, A.A.; Rizvi, S.M.; Graham, P.; Bruchertseifer, F.; Apostolidis, C.; Morgenstern, A. Analysis of patient survival in a Phase I trial of systemic targeted alpha-therapy for metastatic melanoma. *Immunotherapy* **2011**, *3*, 1041–1050. [CrossRef] [PubMed]

80. Gulec, S.A.; Cohen, S.J.; Pennington, K.L.; Zuckier, L.S.; Hauke, R.J.; Horne, H.; Wegener, W.A.; Teoh, N.; Gold, D.V.; Sharkey, R.M.; et al. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: A phase I single-dose escalation trial. *Clin. Cancer Res.* **2011**, *17*, 4091–4100. [CrossRef]

81. Ocean, A.J.; Pennington, K.L.; Guarino, M.J.; Sheikh, A.; Bekaii-Saab, T.; Serafini, A.N.; Lee, D.; Sung, M.W.; Gulec, S.A.; Goldsmith, S.J.; et al. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. *Cancer* **2012**, *118*, 5497–5506. [CrossRef] [PubMed]

82. Picozzi, V.J.; Ramanathan, R.K.; Lowery, M.A.; Ocean, A.J.; Mitchel, E.P.; O'Neil, B.H.; Guarino, M.J.; Conkling, P.R.; Cohen, S.J.; Bahary, N.; et al. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. *Eur. J. Cancer* **2015**, *51*, 1857–1864. [CrossRef]

83. Tagawa, S.T.; Milowsky, M.I.; Morris, M.; Vallabhajosula, S.; Christos, P.; Akhtar, N.H.; Osborne, J.; Goldsmith, S.J.; Larson, S.; Taskar, N.P.; et al. Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. *Clin. Cancer Res.* **2013**, *19*, 5182–5191. [CrossRef]

84. Tagawa, S.T.; Vallabhajosula, S.; Christos, P.J.; Jhanwar, Y.S.; Batra, J.S.; Lam, L.; Osborne, J.; Beltran, H.; Molina, A.M.; Goldsmith, S.J.; et al. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer. *Cancer* **2019**, *125*, 2561–2569. [CrossRef] [PubMed]

85. Batra, J.S.; Niaz, M.J.; Whang, Y.E.; Sheikh, A.; Thomas, C.; Christos, P.; Vallabhajosula, S.; Jhanwar, Y.S.; Molina, A.M.; Nanus, D.M.; et al. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer. *Urol. Oncol.* **2020**, *38*, e9–e16. [CrossRef] [PubMed]

86. Niaz, M.J.; Batra, J.S.; Walsh, R.D.; Ramirez-Fort, M.K.; Vallabhajosula, S.; Jhanwar, Y.S.; Molina, A.M.; Nanus, D.M.; Osborne, J.R.; Bander, N.H.; et al. Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 ((177) Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. *Oncologist* **2020**, *25*, 477–e895. [CrossRef] [PubMed]

87. Stillebroer, A.B.; Boerman, O.C.; Desar, I.M.; Boers-Sonderen, M.J.; van Herpen, C.M.; Langenhuijsen, J.F.; Smith-Jones, P.M.; Oosterwijk, E.; Oyen, W.J.; Mulders, P.F. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. *Eur. Urol.* **2013**, *64*, 478–485. [CrossRef] [PubMed]

88. Muselaers, C.H.; Boers-Sonderen, M.J.; van Oostenbrugge, T.J.; Boerman, O.C.; Desar, I.M.; Stillebroer, A.B.; Mulder, S.F.; van Herpen, C.M.; Langenhuijsen, J.F.; Oosterwijk, E.; et al. Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. *Eur. Urol.* **2016**, *69*, 767–770. [CrossRef] [PubMed]

89. Zhao, Z.; Su, Z.; Zhang, W.; Luo, M.; Wang, H.; Huang, L. A randomized study comparing the effectiveness of microwave ablation radioimmunotherapy and postoperative adjuvant chemoradiation in the treatment of non-small cell lung cancer. *J. BUON* **2016**, *21*, 326–332.

90. Giraudet, A.L.; Cassier, P.A.; Iwao-Fukukawa, C.; Garin, G.; Badel, J.N.; Kryza, D.; Chabaud, S.; Gilles-Afchain, L.; Clapisson, G.; Desuzinges, C.; et al. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. *BMC Cancer* **2018**, *18*, 646. [CrossRef]

91. Modak, S.; Zanzonico, P.; Grkovski, M.; Slotkin, E.K.; Carrasquillo, J.A.; Lyashchenko, S.K.; Lewis, J.S.; Cheung, I.Y.; Heaton, T.; LaQuaglia, M.P.; et al. B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. *J. Clin. Oncol.* **2020**, *38*, 4283–4291. [CrossRef]

92. Lu, G.; Nishio, N.; van den Berg, N.S.; Martin, B.A.; Fakurnejad, S.; van Keulen, S.; Colevas, A.D.; Thurber, G.M.; Rosenthal, E.L. Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates. *Nat. Commun.* **2020**, *11*, 5667. [CrossRef]
75. Kramer, K.; Pandit-Taskar, N.; Humm, J.L.; Zanzonico, P.B.; Haque, S.; Dunkel, I.J.; Wolden, S.L.; Donzelli, M.; Goldman, D.A.; Lewis, J.S.; et al. A phase II study of radioimmunotherapy with intraventricular (131) I-3F8 for medulloblastoma. *Pediatr. Blood Cancer* **2018**, *65*. [CrossRef]

76. Herbertson, R.A.; Tebbutt, N.C.; Lee, F.T.; Gill, S.; Chappell, B.; Cavicchiolo, T.; Saunder, T.; O'Keefe, G.J.; Poon, A.; Lee, S.T.; et al. Targeted chemoradiation in metastatic colorectal cancer: A phase I trial of 131I-huA33 with concurrent capecitabine. *J. Nucl. Med.* **2014**, *55*, 534–539. [CrossRef]

77. Cahan, B.; Leong, L.; Wagman, L.; Yamauchi, D.; Shibata, S.; Wilczynski, S.; Williams, L.E.; Yazaki, P.; Colcher, D.; Frankel, P.; et al. Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma. *Cancer Biother. Radiopharm.* **2017**, *32*, 258–265. [CrossRef]

78. Sahlmann, C.O.; Homayounfar, K.; Niessner, M.; Dyczkowski, J.; Conradi, L.C.; Braulke, F.; Meller, B.; Beissbarth, T.; Ghadimi, B.M.; Meller, J.; et al. Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study. *Cancer* **2017**, *123*, 638–649. [CrossRef] [PubMed]

79. Allen, B.J.; Singla, A.A.; Rizvi, S.M.; Graham, P.; Bruchertseifer, F.; Apostolidis, C.; Morgenstern, A. Analysis of patient survival in a Phase I trial of systemic targeted alpha-therapy for metastatic melanoma. *Immunotherapy* **2011**, *3*, 1041–1050. [CrossRef] [PubMed]

80. Gulec, S.A.; Cohen, S.J.; Pennington, K.L.; Zuckier, L.S.; Hauke, R.J.; Horne, H.; Wegener, W.A.; Teoh, N.; Gold, D.V.; Sharkey, R.M.; et al. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: A phase I single-dose escalation trial. *Clin. Cancer Res.* **2011**, *17*, 4091–4100. [CrossRef]

81. Ocean, A.J.; Pennington, K.L.; Guarino, M.J.; Sheikh, A.; Bekaii-Saab, T.; Serafini, A.N.; Lee, D.; Sung, M.W.; Gulec, S.A.; Goldsmith, S.J.; et al. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. *Cancer* **2012**, *118*, 5497–5506. [CrossRef] [PubMed]

82. Picozzi, V.J.; Ramanathan, R.K.; Lowery, M.A.; Ocean, A.J.; Mitchel, E.P.; O'Neil, B.H.; Guarino, M.J.; Conkling, P.R.; Cohen, S.J.; Bahary, N.; et al. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. *Eur. J. Cancer* **2015**, *51*, 1857–1864. [CrossRef]

83. Tagawa, S.T.; Milowsky, M.I.; Morris, M.; Vallabhajosula, S.; Christos, P.; Akhtar, N.H.; Osborne, J.; Goldsmith, S.J.; Larson, S.; Taskar, N.P.; et al. Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. *Clin. Cancer Res.* **2013**, *19*, 5182–5191. [CrossRef]

84. Tagawa, S.T.; Vallabhajosula, S.; Christos, P.J.; Jhanwar, Y.S.; Batra, J.S.; Lam, L.; Osborne, J.; Beltran, H.; Molina, A.M.; Goldsmith, S.J.; et al. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer. *Cancer* **2019**, *125*, 2561–2569. [CrossRef] [PubMed]

85. Batra, J.S.; Niaz, M.J.; Whang, Y.E.; Sheikh, A.; Thomas, C.; Christos, P.; Vallabhajosula, S.; Jhanwar, Y.S.; Molina, A.M.; Nanus, D.M.; et al. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer. *Urol. Oncol.* **2020**, *38*, e9–e16. [CrossRef] [PubMed]

86. Niaz, M.J.; Batra, J.S.; Walsh, R.D.; Ramirez-Fort, M.K.; Vallabhajosula, S.; Jhanwar, Y.S.; Molina, A.M.; Nanus, D.M.; Osborne, J.R.; Bander, N.H.; et al. Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 ((177) Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. *Oncologist* **2020**, *25*, 477–e895. [CrossRef] [PubMed]

87. Stillebroer, A.B.; Boerman, O.C.; Desar, I.M.; Boers-Sonderen, M.J.; van Herpen, C.M.; Langenhuijsen, J.F.; Smith-Jones, P.M.; Oosterwijk, E.; Oyen, W.J.; Mulders, P.F. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. *Eur. Urol.* **2013**, *64*, 478–485. [CrossRef] [PubMed]

88. Muselaers, C.H.; Boers-Sonderen, M.J.; van Oostenbrugge, T.J.; Boerman, O.C.; Desar, I.M.; Stillebroer, A.B.; Mulder, S.F.; van Herpen, C.M.; Langenhuijsen, J.F.; Oosterwijk, E.; et al. Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. *Eur. Urol.* **2016**, *69*, 767–770. [CrossRef] [PubMed]

89. Zhao, Z.; Su, Z.; Zhang, W.; Luo, M.; Wang, H.; Huang, L. A randomized study comparing the effectiveness of microwave ablation radioimmunotherapy and postoperative adjuvant chemoradiation in the treatment of non-small cell lung cancer. *J. BUON* **2016**, *21*, 326–332.

90. Giraudet, A.L.; Cassier, P.A.; Iwao-Fukukawa, C.; Garin, G.; Badel, J.N.; Kryza, D.; Chabaud, S.; Gilles-Afchain, L.; Clapisson, G.; Desuzinges, C.; et al. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. *BMC Cancer* **2018**, *18*, 646. [CrossRef]

91. Modak, S.; Zanzonico, P.; Grkovski, M.; Slotkin, E.K.; Carrasquillo, J.A.; Lyashchenko, S.K.; Lewis, J.S.; Cheung, I.Y.; Heaton, T.; LaQuaglia, M.P.; et al. B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. *J. Clin. Oncol.* **2020**, *38*, 4283–4291. [CrossRef]

92. Lu, G.; Nishio, N.; van den Berg, N.S.; Martin, B.A.; Fakurnejad, S.; van Keulen, S.; Colevas, A.D.; Thurber, G.M.; Rosenthal, E.L. Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates. *Nat. Commun.* **2020**, *11*, 5667. [CrossRef]
93. White, J.M.; Escorcia, F.E.; Viola, N.T. Perspectives on metals-based radioimmunotherapy (RIT): Moving forward. *Theranostics* **2021**, *11*, 6293–6314. [CrossRef]

94. Nelson, B.J.B.; Andersson, J.D.; Wuest, F. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications. *Pharmaceutics* **2020**, *13*, 49. [CrossRef]

95. Rondon, A.; Mahri, S.; Morales-Yanez, F.; Dumoulin, M.; Vanbever, R. Protein Engineering Strategies for Improved Pharmacokinetics. *Adv. Funct. Mater.* **2021**, *31*, 2101633. [CrossRef]

96. Kholodenko, R.V.; Kalinovsky, D.V.; Doronin, I.I.; Ponomarev, E.D.; Kholodenko, I.V. Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations. *Curr. Med. Chem.* **2019**, *26*, 396–426. [CrossRef] [PubMed]

97. Nelson, A.L. Antibody fragments: Hope and hype. *MAbs* **2010**, *2*, 77–83. [CrossRef] [PubMed]

98. Nelson, A.L.; Reichert, J.M. Development trends for therapeutic antibody fragments. *Nat. Biotechnol.* **2009**, *27*, 331–337. [CrossRef] [PubMed]

99. Casey, J.L.; Napier, M.P.; King, D.J.; Pedley, R.B.; Chaplin, L.C.; Weir, N.; Skelton, L.; Green, A.J.; Hope-Stone, L.D.; Yarranton, G.T.; et al. Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: A clinical phase I/II study. *Br. J. Cancer* **2002**, *86*, 1401–1410. [CrossRef] [PubMed]

100. Vermeer, A.W.P.; Norde, W. The Thermal Stability of Immunoglobulin: Unfolding and Aggregation of a Multi-Domain Protein. *Biophys. J.* **2000**, *78*, 394–404. [CrossRef]

101. Aloj, L.; D'Ambrosio, L.; Aurilio, M.; Morisco, A.; Frigeri, F.; Caraco, C.; Di Gennaro, F.; Capobianco, G.; Giovannoni, L.; Menssen, H.D.; et al. Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. *Eur. J. Nucl. Med. Mol. Imaging* **2014**, *41*, 867–877. [CrossRef]

102. Gonzalez, G.P.; Garcia, I.G.; Gonzalez, J.G.; Sanchez, L.P.; Mirabal, M.V.; Marin, C.C.; Ruiz, F.L.; Iglesias, E.G.; de Queralta, R.L.; Toirac, R.R.; et al. Phase I clinical trial of the (131)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment. *Cancer Biother. Radiopharm.* **2011**, *26*, 353–363. [CrossRef]

103. Wu, L.; Yang, Y.F.; Ge, N.J.; Shen, S.Q.; Liang, J.; Wang, Y.; Zhou, W.P.; Shen, F.; Wu, M.C. Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: Interim safety and survival data from 110 patients. *Cancer Biother. Radiopharm.* **2010**, *25*, 657–663. [CrossRef]

104. Wu, L.; Yang, Y.F.; Ge, N.J.; Shen, S.Q.; Liang, J.; Wang, Y.; Zhou, W.P.; Shen, F.; Wu, M.C. Hepatic artery injection of (1)(3)(1)I-labeled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: A prospective nonrandomized study. *Eur. J. Nucl. Med. Mol. Imaging* **2012**, *39*, 1306–1315. [CrossRef] [PubMed]

105. Li, Z.; Zhou, J.X.; Ren, J.Z.; Zhang, W.J.; Han, X.W. Clinical value of iodine [131I] metuximab infusion combined with TACE for treatment of patients with post-intervention relapse of mid or advanced stage hepatocellular carcinoma. *Zhonghua Gan Zang Bing Za Zhi* **2013**, *21*, 728–733. [CrossRef]

106. Bian, H.; Zheng, J.S.; Nan, G.; Li, R.; Chen, C.; Hu, C.X.; Zhang, Y.; Sun, B.; Wang, X.L.; Cui, S.C.; et al. Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation. *J. Natl. Cancer Inst.* **2014**, *106*. [CrossRef]

107. Li, J.; Xing, J.; Yang, Y.; Liu, J.; Wang, W.; Xia, Y.; Yan, Z.; Wang, K.; Wu, D.; Wu, L.; et al. Adjuvant (131)I-metuximab for hepatocellular carcinoma after liver resection: A randomised, controlled, multicentre, open-label, phase 2 trial. *Lancet Gastroenterol. Hepatol.* **2020**, *5*, 548–560. [CrossRef]

108. Breitz, H.B.; Tyler, A.; Bjorn, M.J.; Lesley, T.; Weiden, P.L. Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy. *Clin. Nucl. Med.* **1997**, *22*, 615–620. [CrossRef] [PubMed]

109. Quigley, A.M.; Gnanasegaran, G.; Buscombe, J.R.; Hilson, A.J. Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections. *Med. Princ. Pract.* **2008**, *17*, 447–452. [CrossRef] [PubMed]

110. Klotz, S.A.; Yates, S.; Smith, S.L.; Dudley, S., Jr.; Schmidt, J.O.; Shirazi, F.M. Scorpion Stings and Antivenom Use in Arizona. *Am. J. Med.* **2021**, *134*, 1034–1038. [CrossRef] [PubMed]

111. Cocchio, C.; Johnson, J.; Clifton, S. Review of North American pit viper antivenoms. *Am. J. Health Syst. Pharm* **2020**, *77*, 175–187. [CrossRef] [PubMed]

112. Chen, Z.N.; Mi, L.; Xu, J.; Song, F.; Zhang, Q.; Zhang, Z.; Xing, J.L.; Bian, H.J.; Jiang, J.L.; Wang, X.H.; et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical phase I/II trials. *Int. J. Radiat. Oncol. Biol. Phys.* **2006**, *65*, 435–444. [CrossRef]

113. Xu, J.; Shen, Z.-Y.; Chen, X.-G.; Zhang, Q.; Bian, H.-J.; Zhu, P.; Xu, H.-Y.; Song, F.; Yang, X.-M.; Mi, L.; et al. A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation. *Hepatology* **2007**, *45*, 269–276. [CrossRef]

114. Xu, J.; Xu, H.-Y.; Zhang, Q.; Song, F.; Jiang, J.-L.; Yang, X.-M.; Mi, L.; Wen, N.; Tian, R.; Wang, L.; et al. HAb18G/CD147 Functions in Invasion and Metastasis of Hepatocellular Carcinoma. *Mol. Cancer Res.* **2007**, *5*, 605–614. [CrossRef]

115. Chen, W.; Yuan, Y.; Jiang, X. Antibody and antibody fragments for cancer immunotherapy. *J. Control. Release* **2020**, *328*, 395–406. [CrossRef]

116. Kamiya, T.; Seow, S.V.; Wong, D.; Robinson, M.; Campana, D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. *J. Clin. Investig.* **2019**, *129*, 2094–2106. [CrossRef] [PubMed]

117. Markham, A. Brolucizumab: First Approval. *Drugs* **2019**, *79*, 1997–2000. [CrossRef] [PubMed]

118. Massa, S.; Xavier, C.; Muyldermans, S.; Devoogdt, N. Emerging site-specific bioconjugation strategies for radioimmunotracer development. *Expert Opin. Drug Deliv.* **2016**, *13*, 1149–1163. [CrossRef] [PubMed]
93. White, J.M.; Escorcia, F.E.; Viola, N.T. Perspectives on metals-based radioimmunotherapy (RIT): Moving forward. *Theranostics* **2021**, *11*, 6293–6314. [CrossRef]

94. Nelson, B.J.B.; Andersson, J.D.; Wuest, F. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications. *Pharmaceutics* **2020**, *13*, 49. [CrossRef]

95. Rondon, A.; Mahri, S.; Morales-Yanez, F.; Dumoulin, M.; Vanbever, R. Protein Engineering Strategies for Improved Pharmacokinetics. *Adv. Funct. Mater.* **2021**, *31*, 2101633. [CrossRef]

96. Kholodenko, R.V.; Kalinovsky, D.V.; Doronin, I.I.; Ponomarev, E.D.; Kholodenko, I.V. Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations. *Curr. Med. Chem.* **2019**, *26*, 396–426. [CrossRef] [PubMed]

97. Nelson, A.L. Antibody fragments: Hope and hype. *MAbs* **2010**, *2*, 77–83. [CrossRef] [PubMed]

98. Nelson, A.L.; Reichert, J.M. Development trends for therapeutic antibody fragments. *Nat. Biotechnol.* **2009**, *27*, 331–337. [CrossRef] [PubMed]

99. Casey, J.L.; Napier, M.P.; King, D.J.; Pedley, R.B.; Chaplin, L.C.; Weir, N.; Skelton, L.; Green, A.J.; Hope-Stone, L.D.; Yarranton, G.T.; et al. Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: A clinical phase I/II study. *Br. J. Cancer* **2002**, *86*, 1401–1410. [CrossRef] [PubMed]

100. Vermeer, A.W.P.; Norde, W. The Thermal Stability of Immunoglobulin: Unfolding and Aggregation of a Multi-Domain Protein. *Biophys. J.* **2000**, *78*, 394–404. [CrossRef]

101. Aloj, L.; D'Ambrosio, L.; Aurilio, M.; Morisco, A.; Frigeri, F.; Caraco, C.; Di Gennaro, F.; Capobianco, G.; Giovannoni, L.; Menssen, H.D.; et al. Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. *Eur. J. Nucl. Med. Mol. Imaging* **2014**, *41*, 867–877. [CrossRef]

102. Gonzalez, G.P.; Garcia, I.G.; Gonzalez, J.G.; Sanchez, L.P.; Mirabal, M.V.; Marin, C.C.; Ruiz, F.L.; Iglesias, E.G.; de Queralta, R.L.; Toirac, R.R.; et al. Phase I clinical trial of the (131)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment. *Cancer Biother. Radiopharm.* **2011**, *26*, 353–363. [CrossRef]

103. Wu, L.; Yang, Y.F.; Ge, N.J.; Shen, S.Q.; Liang, J.; Wang, Y.; Zhou, W.P.; Shen, F.; Wu, M.C. Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: Interim safety and survival data from 110 patients. *Cancer Biother. Radiopharm.* **2010**, *25*, 657–663. [CrossRef]

104. Wu, L.; Yang, Y.F.; Ge, N.J.; Shen, S.Q.; Liang, J.; Wang, Y.; Zhou, W.P.; Shen, F.; Wu, M.C. Hepatic artery injection of (1)(3)(1)I-labeled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: A prospective nonrandomized study. *Eur. J. Nucl. Med. Mol. Imaging* **2012**, *39*, 1306–1315. [CrossRef] [PubMed]

105. Li, Z.; Zhou, J.X.; Ren, J.Z.; Zhang, W.J.; Han, X.W. Clinical value of iodine [131I] metuximab infusion combined with TACE for treatment of patients with post-intervention relapse of mid or advanced stage hepatocellular carcinoma. *Zhonghua Gan Zang Bing Za Zhi* **2013**, *21*, 728–733. [CrossRef]

106. Bian, H.; Zheng, J.S.; Nan, G.; Li, R.; Chen, C.; Hu, C.X.; Zhang, Y.; Sun, B.; Wang, X.L.; Cui, S.C.; et al. Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation. *J. Natl. Cancer Inst.* **2014**, *106*. [CrossRef]

107. Li, J.; Xing, J.; Yang, Y.; Liu, J.; Wang, W.; Xia, Y.; Yan, Z.; Wang, K.; Wu, D.; Wu, L.; et al. Adjuvant (131)I-metuximab for hepatocellular carcinoma after liver resection: A randomised, controlled, multicentre, open-label, phase 2 trial. *Lancet Gastroenterol. Hepatol.* **2020**, *5*, 548–560. [CrossRef]

108. Breitz, H.B.; Tyler, A.; Bjorn, M.J.; Lesley, T.; Weiden, P.L. Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy. *Clin. Nucl. Med.* **1997**, *22*, 615–620. [CrossRef] [PubMed]

109. Quigley, A.M.; Gnanasegaran, G.; Buscombe, J.R.; Hilson, A.J. Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections. *Med. Princ. Pract.* **2008**, *17*, 447–452. [CrossRef] [PubMed]

110. Klotz, S.A.; Yates, S.; Smith, S.L.; Dudley, S., Jr.; Schmidt, J.O.; Shirazi, F.M. Scorpion Stings and Antivenom Use in Arizona. *Am. J. Med.* **2021**, *134*, 1034–1038. [CrossRef] [PubMed]

111. Cocchio, C.; Johnson, J.; Clifton, S. Review of North American pit viper antivenoms. *Am. J. Health Syst. Pharm* **2020**, *77*, 175–187. [CrossRef] [PubMed]

112. Chen, Z.N.; Mi, L.; Xu, J.; Song, F.; Zhang, Q.; Zhang, Z.; Xing, J.L.; Bian, H.J.; Jiang, J.L.; Wang, X.H.; et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical phase I/II trials. *Int. J. Radiat. Oncol. Biol. Phys.* **2006**, *65*, 435–444. [CrossRef]

113. Xu, J.; Shen, Z.-Y.; Chen, X.-G.; Zhang, Q.; Bian, H.-J.; Zhu, P.; Xu, H.-Y.; Song, F.; Yang, X.-M.; Mi, L.; et al. A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation. *Hepatology* **2007**, *45*, 269–276. [CrossRef]

114. Xu, J.; Xu, H.-Y.; Zhang, Q.; Song, F.; Jiang, J.-L.; Yang, X.-M.; Mi, L.; Wen, N.; Tian, R.; Wang, L.; et al. HAb18G/CD147 Functions in Invasion and Metastasis of Hepatocellular Carcinoma. *Mol. Cancer Res.* **2007**, *5*, 605–614. [CrossRef]

115. Chen, W.; Yuan, Y.; Jiang, X. Antibody and antibody fragments for cancer immunotherapy. *J. Control. Release* **2020**, *328*, 395–406. [CrossRef]

116. Kamiya, T.; Seow, S.V.; Wong, D.; Robinson, M.; Campana, D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. *J. Clin. Investig.* **2019**, *129*, 2094–2106. [CrossRef] [PubMed]

117. Markham, A. Brolucizumab: First Approval. *Drugs* **2019**, *79*, 1997–2000. [CrossRef] [PubMed]

118. Massa, S.; Xavier, C.; Muyldermans, S.; Devoogdt, N. Emerging site-specific bioconjugation strategies for radioimmunotracer development. *Expert Opin. Drug Deliv.* **2016**, *13*, 1149–1163. [CrossRef] [PubMed]
119. Alfaleh, M.A.; Alsaab, H.O.; Mahmoud, A.B.; Alkayyal, A.A.; Jones, M.L.; Mahler, S.M.; Hashem, A.M. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. *Front. Immunol.* **2020**, *11*, 1986. [CrossRef]

120. Sharkey, R.M.; Karacay, H.; Cardillo, T.M.; Chang, C.H.; McBride, W.J.; Rossi, E.A.; Horak, I.D.; Goldenberg, D.M. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. *Clin. Cancer Res.* **2005**, *11*, 7109s–7121s. [CrossRef]

121. Rondon, A.; Degoul, F. Antibody Pretargeting Based on Bioorthogonal Click Chemistry for Cancer Imaging and Targeted Radionuclide Therapy. *Bioconjug Chem.* **2020**, *31*, 159–173. [CrossRef] [PubMed]

122. Labrijn, A.F.; Janmaat, M.L.; Reichert, J.M.; Parren, P. Bispecific antibodies: A mechanistic review of the pipeline. *Nat. Rev. Drug Discov.* **2019**, *18*, 585–608. [CrossRef] [PubMed]

123. Shim, H. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations. *Biomolecules* **2020**, *10*, 360. [CrossRef] [PubMed]

124. Scott, L.J.; Kim, E.S. Emicizumab-kxwh: First Global Approval. *Drugs* **2018**, *78*, 269–274. [CrossRef]

125. Salaun, P.Y.; Campion, L.; Bournaud, C.; Faivre-Chauvet, A.; Vuillez, J.P.; Taieb, D.; Ansquer, C.; Rousseau, C.; Borson-Chazot, F.; Bardet, S.; et al. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: Biomarker response and survival improvement. *J. Nucl. Med.* **2012**, *53*, 1185–1192. [CrossRef]

126. Schoffelen, R.; Boerman, O.C.; Goldenberg, D.M.; Sharkey, R.M.; van Herpen, C.M.; Franssen, G.M.; McBride, W.J.; Chang, C.H.; Rossi, E.A.; van der Graaf, W.T.; et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: First clinical results. *Br. J. Cancer* **2013**, *109*, 934–942. [CrossRef] [PubMed]

127. Bodet-Milin, C.; Ferrer, L.; Rauscher, A.; Masson, D.; Rbah-Vidal, L.; Faivre-Chauvet, A.; Cerato, E.; Rousseau, C.; Hureaux, J.; Couturier, O.; et al. Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. *Front. Med.* **2015**, *2*, 84. [CrossRef]

128. Rossi, E.A.; Goldenberg, D.M.; Cardillo, T.M.; McBride, W.J.; Sharkey, R.M.; Chang, C.H. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 6841–6846. [CrossRef]
119. Alfaleh, M.A.; Alsaab, H.O.; Mahmoud, A.B.; Alkayyal, A.A.; Jones, M.L.; Mahler, S.M.; Hashem, A.M. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. *Front. Immunol.* **2020**, *11*, 1986. [CrossRef]

120. Sharkey, R.M.; Karacay, H.; Cardillo, T.M.; Chang, C.H.; McBride, W.J.; Rossi, E.A.; Horak, I.D.; Goldenberg, D.M. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. *Clin. Cancer Res.* **2005**, *11*, 7109s–7121s. [CrossRef]

121. Rondon, A.; Degoul, F. Antibody Pretargeting Based on Bioorthogonal Click Chemistry for Cancer Imaging and Targeted Radionuclide Therapy. *Bioconjug Chem.* **2020**, *31*, 159–173. [CrossRef] [PubMed]

122. Labrijn, A.F.; Janmaat, M.L.; Reichert, J.M.; Parren, P. Bispecific antibodies: A mechanistic review of the pipeline. *Nat. Rev. Drug Discov.* **2019**, *18*, 585–608. [CrossRef] [PubMed]

123. Shim, H. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations. *Biomolecules* **2020**, *10*, 360. [CrossRef] [PubMed]

124. Scott, L.J.; Kim, E.S. Emicizumab-kxwh: First Global Approval. *Drugs* **2018**, *78*, 269–274. [CrossRef]

125. Salaun, P.Y.; Campion, L.; Bournaud, C.; Faivre-Chauvet, A.; Vuillez, J.P.; Taieb, D.; Ansquer, C.; Rousseau, C.; Borson-Chazot, F.; Bardet, S.; et al. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: Biomarker response and survival improvement. *J. Nucl. Med.* **2012**, *53*, 1185–1192. [CrossRef]

126. Schoffelen, R.; Boerman, O.C.; Goldenberg, D.M.; Sharkey, R.M.; van Herpen, C.M.; Franssen, G.M.; McBride, W.J.; Chang, C.H.; Rossi, E.A.; van der Graaf, W.T.; et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: First clinical results. *Br. J. Cancer* **2013**, *109*, 934–942. [CrossRef] [PubMed]

127. Bodet-Milin, C.; Ferrer, L.; Rauscher, A.; Masson, D.; Rbah-Vidal, L.; Faivre-Chauvet, A.; Cerato, E.; Rousseau, C.; Hureaux, J.; Couturier, O.; et al. Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. *Front. Med.* **2015**, *2*, 84. [CrossRef]

128. Rossi, E.A.; Goldenberg, D.M.; Cardillo, T.M.; McBride, W.J.; Sharkey, R.M.; Chang, C.H. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 6841–6846. [CrossRef]